March 30, 2014 / 11:31 PM / 3 years ago

Japan's Takeda, Dainippon get EU nod for schizophrenia drug

1 Min Read

TOKYO, March 31 (Reuters) - Takeda Pharmaceutical Co Ltd and Dainippon Sumitomo Pharma Co Ltd said on Monday the European Commission had given them marketing authorisation for Latuda, a once-a-day oral treatment for schizophrenia in adults.

Sunovion Pharmaceuticals Europe Ltd, a subsidiary of Dainippon Sumitomo Pharma, will market Latuda in the UK, and Takeda subsidiaries will market the drug across Europe, they said in a joint statement. (Reporting by Dominic Lau; Editing by John Mair)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below